Biotech entity
The clearest coverage concentration is pharma: 13 of 16 stories, with the rest divided among 3 other categories. Sentiment skews more negative than the wider beat, at 44% negative against 19% across all 601 Biotech stories in the same window.
Last mentioned: Aug 4, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 44 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 13 of 16 stories, with the rest divided among 3 other categories. Sentiment skews more negative than the wider beat, at 44% negative against 19% across all 601 Biotech stories in the same window. Of the tracked stories, 7 of 16 also mention Pfizer, the most common co-covered peer. Each story carries 2.3 original sources on average, compared with 3.7 for the broader beat in this window. The 161-day window averages about 0.7 stories each week. The busiest single day carried 3. Their average consequence score of 6.3 runs above the beat's 6.2 for that window. GSK appears in 16 tracked Biotech stories published from February 25, 2026 through August 4, 2026.
Computed from the 16 stories linked to this entity, with beat comparisons drawn from all 601 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GSK. Shared-story counts are live from our verified record — not editorial picks.
Target Deadline
Goal for participating nations to reach the 90-70-90 elimination milestones.
SDG Deadline
Target year for reducing neonatal mortality to 12 per 1,000 live births.
Source Publication
Related article published, summarizing key highlights from the earnings call.
GSK Q1 Earnings Call
GSK announced strong Q1 sales growth and reaffirmed full-year guidance during their earnings call.
Mass Vaccination
UKHSA and NHS begin large-scale immunization drive using the Bexsero vaccine.
NHS Alert Issued
A formal alert is sent to NHS trusts and GP surgeries across England to prepare for increased vaccine demand.
Strain Confirmation
Laboratory results confirm Meningitis B as the causative agent; two fatalities reported.
UKHSA Briefing
Health chiefs describe the outbreak as 'explosive' and 'unprecedented' in national alerts.
Initial Reports
First cases of severe meningitis reported among students at the University of Kent.
Vaccine Mobilization
Emergency stocks of MenACWY and MenB vaccines are diverted to regional hubs.
Expected Response
The Trump administration is expected to file its initial legal defense regarding executive agency authority.
Outbreak Confirmed
Public health officials confirm multiple linked cases and at least one fatality.
Fund Launch
Jacinda Ardern officially unveils the dedicated fund for Pacific cervical cancer elimination.
Initial Cases Reported
First reports of severe meningococcal symptoms emerge in student housing.
Surveillance Data Review
UKHSA identifies a rising trend in meningococcal strain activity among young adults.
Public Announcement
Arizona and other state attorneys general publicly detail the health risks associated with the vaccine rollback.
Lawsuit Filed
A coalition of states files a formal complaint against the Trump administration in federal court.
Regional Assessment
Health audits reveal critical gaps in HPV vaccine coverage across the Pacific Islands.
Current Assessment
UN report confirms 4.9 million deaths, indicating a slowdown in progress.
WHO Global Strategy
WHO launches the global strategy to accelerate the elimination of cervical cancer.
Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
GSK's strong Q1 performance signals growth in biotech innovation, with sales up and full-year guidance intact, potentially accelerating clinical trials and FDA approvals. This development underscores opportunities in gene therapy and vaccines for biotech firms. Investors in the sector should watch for ripple effects on R&D investments.
Source: finance.yahoo.com · Yahoo! News
The Health Secretary has committed to an immediate expansion of meningitis vaccine supplies following a reported increase in cases to 27. This regulatory intervention aims to bolster public immunity and prevent a wider outbreak of the life-threatening infection.
The NHS has issued an urgent health alert across England as students begin receiving critical meningitis vaccinations to combat a seasonal rise in invasive meningococcal disease. Health officials are prioritizing first-year university students to prevent potential outbreaks in high-density campus environments.
Public health authorities have initiated an emergency vaccination campaign for students following a series of fatal meningitis cases in the UK. The drive aims to contain the spread of invasive meningococcal disease within high-risk educational environments through the rapid deployment of MenACWY and MenB vaccines.
A new United Nations report reveals that approximately 4.9 million children under the age of five died in 2024, highlighting persistent gaps in global healthcare equity. While mortality rates have declined historically, the data underscores a critical need for expanded access to vaccines, antibiotics, and nutritional interventions.
UK health officials are responding to a severe Meningitis B outbreak at the University of Kent that has left two students dead and 11 others seriously ill. Described as "explosive" and "unprecedented," the cluster has triggered an urgent mass vaccination campaign and heightened surveillance across the region.
Health authorities have confirmed Meningitis B as the strain responsible for a recent outbreak resulting in two fatalities. The confirmation is expected to intensify the focus on regional vaccination coverage and the efficacy of current immunization protocols against emerging clusters.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
Former New Zealand Prime Minister Jacinda Ardern has launched a dedicated health fund to combat the disproportionately high rates of cervical cancer in Pacific Island nations. The initiative focuses on scaling HPV DNA testing and vaccination programs to meet WHO elimination targets by 2030.
FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.
The CDC has issued urgent travel advisories for several popular tourist destinations following a confirmed spread of poliovirus. This development signals a significant setback for global eradication efforts and is expected to drive a surge in demand for inactivated poliovirus vaccines (IPV).
Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
California and 14 other states have filed a federal lawsuit against the Trump administration, challenging recent modifications to the recommended childhood immunization schedule. The coalition argues that these changes lack scientific justification and threaten to undermine decades of public health progress.
A coalition of over a dozen states, led by Arizona, has filed a federal lawsuit against the Trump administration to block the rollback of childhood vaccine recommendations. The plaintiffs argue that the changes to CDC guidelines bypass scientific protocols and present an immediate threat to national public health safety.
GSK is linked from 16 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
